Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM.

Clin Pharmacol Ther. 2012 Jul;92(1):87-95. doi: 10.1038/clpt.2011.371. Epub 2012 May 16.

PMID:
22588608
2.

Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.

Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, Bhatty S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshees AL, Robinson SW, Blitzer MG, McArdle PF, Brown L, Jeng LJ, Zhao RY, Ambulos N, Vesely MR.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):76-84. doi: 10.1002/ajmg.c.31396. Epub 2014 Mar 10.

PMID:
24616408
3.

A surveillance tool to support quality assurance and research in personalized medicine.

Khan NA, Peterson JF.

AMIA Annu Symp Proc. 2011;2011:701-8. Epub 2011 Oct 22.

PMID:
22195126
4.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
5.

Personalized approaches to clopidogrel therapy: are we there yet?

Anderson CD, Biffi A, Greenberg SM, Rosand J.

Stroke. 2010 Dec;41(12):2997-3002. doi: 10.1161/STROKEAHA.110.594069. Epub 2010 Oct 28. Review.

PMID:
21030701
6.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29.

PMID:
22464343
7.

Genetic variability in response to clopidogrel therapy and its clinical implications.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K.

Thromb Haemost. 2011 May;105 Suppl 1:S55-9. doi: 10.1160/THS10-11-0747. Epub 2011 Apr 11. Review.

PMID:
21479337
8.

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Johnson JA, Cavallari LH.

Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. Review.

PMID:
23686351
9.

CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.

Peters BJ, Harmsze AM, ten Berg JM, Maitland-van der Zee AH, Tjoeng MM, de Boer A, Deneer VH.

Pharmacogenomics. 2011 Feb;12(2):141-4. doi: 10.2217/pgs.10.211. No abstract available.

PMID:
21332306
10.

Establishment of a CYP2C19 genotyping assay for clinical use.

Cervinski MA, Schwab MC, Lefferts JA, Lewis LD, Lebel KA, Tyropolis AM, Pflueger SM, Tsongalis GJ.

Am J Clin Pathol. 2013 Feb;139(2):202-7. doi: 10.1309/AJCP9K2KDOCPCBSV.

PMID:
23355205
11.

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Shahin MH, Johnson JA.

Curr Opin Cardiol. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Review.

PMID:
23478884
12.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

PMID:
21716271
13.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
14.

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.

Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, Von Beckerath N, Mehilli J, Schömig A, Schuster T, Kastrati A.

J Thromb Haemost. 2010 Aug;8(8):1685-93. doi: 10.1111/j.1538-7836.2010.03921.x. Epub 2010 May 21.

PMID:
20492469
15.

Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.

Fontana P, Cattaneo M, Combescure C, Reny JL.

J Am Heart Assoc. 2013 Mar 27;2(2):e000131. doi: 10.1161/JAHA.112.000131.

PMID:
23537811
16.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
17.

Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

Fuster V, Sweeny JM.

JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566. No abstract available.

PMID:
20978263
18.

Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.

George J, Doney A, Palmer CN, Lang CC.

Cardiovasc Ther. 2010 Jun;28(3):135-8. doi: 10.1111/j.1755-5922.2010.00176.x. No abstract available.

PMID:
20557312
19.

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.

PMID:
23698643
20.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

PMID:
20801494

Supplemental Content

Support Center